BGA
BIS icon

Belmont Global Advisors’s ProShares UltraShort NASDAQ Biotechnology BIS Stock Holding History

Belmont Global Advisors’s Portfolio BIS Stock Details BIS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-1,250
Closed -$891K – 131
2014
Q1 		$891K Buy
+1,250
New +$834K 0.75% 38

Other funds holding BIS

HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
Zurich Cantonal Bank
Zurich Cantonal Bank Zurich, Switzerland $46B AUM 27.59% 1-Year Est. Return
ST
Spot Trading Chicago, Illinois $5.81B AUM 22.41% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
U
UBS Zurich, Switzerland $136B AUM 16.36% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Belmont Global Advisors's BIS Position: Q2 2014 in Review

Belmont Global Advisors sold out of ProShares UltraShort NASDAQ Biotechnology (BIS) in Q2 2014, closing a stake of 1,250 shares — an estimated $891K sold.

Belmont Global Advisors first reported a position in BIS in Q1 2014 and held it in 1 quarter. The position peaked at $891K in Q1 2014. 9 funds tracked by Wall St. Rank hold BIS as of Q2 2014.

  • Belmont Global Advisors reported no remaining ProShares UltraShort NASDAQ Biotechnology position as of Q2 2014 after selling out during the quarter.
  • Belmont Global Advisors sold 1,250 ProShares UltraShort NASDAQ Biotechnology shares in Q2 2014, an estimated $891K.
  • Belmont Global Advisors first reported a position in ProShares UltraShort NASDAQ Biotechnology in Q1 2014 and held it in 1 quarter.
  • Belmont Global Advisors's ProShares UltraShort NASDAQ Biotechnology position peaked at $891K in Q1 2014.
  • 9 funds tracked by Wall St. Rank held ProShares UltraShort NASDAQ Biotechnology as of Q2 2014.

Based on Belmont Global Advisors's 13F filing for Q2 2014, filed 14 Aug 2014.